Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



AstraZeneca's Fishy FDA Approval

The Food and Drug Administration recently approved AstraZeneca's (NYSE: AZN  ) Epanova, adding it to the growing list of omega-3 fish oil drugs that includes GlaxoSmithKline's (NYSE: GSK  ) Lovaza and Amarin's (NASDAQ: AMRN  ) Vascepa.

In the following video, senior biotech specialist Brian Orelli and health-care analyst David Williamson discus the market dynamics for fish oil drugs, which has Lovaza dominating the market even though Vascepa is arguably a better drug.

We'll have to see whether AstraZeneca can use its marketing muscle to succeed where Amarin has failed. Epanova has some advantages because it can be taken just once a day and doesn't have to be taken with food, but it's debatable whether thosae are big enough to get patients to switch.

Whether Epanova takes market from Lovaza or not, AstraZeneca's and GlaxoSmithKline's dividends are safe
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 20, 2014, at 6:54 PM, rdhitchcock wrote:

    Brian Orelli: "Epanova has some advantages because it can be taken just once a day and doesn't have to be taken with food."

    Epanova also has some very negative disadvantages as well.....mainly raising LDL-C and Apo B which are both important biomarkers of cardiovascular risk.

    Also, compare results from a 4g dose of Epanova to Vascepa in regards to cholesterol, Non HDL-C, hsCRP, ApoC-III. Vascepa is a much better drug.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2963778, ~/Articles/ArticleHandler.aspx, 8/29/2015 3:01:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 17 hours ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 3:59 PM
AMRN $2.23 Up +0.14 +6.70%
Amarin Corp plc (A… CAPS Rating: ****
AZN $31.67 Up +0.06 +0.19%
AstraZeneca plc (A… CAPS Rating: ****
GSK $41.25 Up +0.04 +0.10%
GlaxoSmithKline CAPS Rating: ****